Korean Circ J.  2023 Dec;53(12):811-812. 10.4070/kcj.2023.0289.

Who Can Stop This Fire?

• Lee HJ
• Kim IC

• KMID: 2548787
• DOI: http://doi.org/10.4070/kcj.2023.0289

Reference

1. Cooper LT Jr. Myocarditis. N Engl J Med. 2009; 360:1526–1538. PMID: 19357408.

2. Zarifa A, Kim JW, Lopez-Mattei J, Palaskas N, Iliescu C, Kim PY. Cardiac toxicities associated with immune checkpoints inhibitors: mechanisms, manifestations and management. Korean Circ J. 2021; 51:579–597. PMID: 34227272.

3. Ching S, Yue CS. Fulminant myocarditis after SARS-CoV-2 mRNA vaccine successfully managed with biventricular Impella support: multimodality imaging follow-up. Korean Circ J. 2022; 52:797–798. PMID: 36217602.

4. Ammirati E, Frigerio M, Adler ED, et al. Management of acute myocarditis and chronic inflammatory cardiomyopathy: an expert consensus document. Circ Heart Fail. 2020; 13:e007405. PMID: 33176455.

5. Nagai T, Inomata T, Kohno T, et al. JCS 2023 guideline on the diagnosis and treatment of myocarditis. Circ J. 2023; 87:674–754. PMID: 36908170.

6. Kim KJ, Park JB, Lee SP, Kim HK, Kim YJ. Thalidomide and a dipeptidyl peptidase 4 inhibitor in a rat model of experimental autoimmune myocarditis. Korean Circ J. 2023; 53:795–810. PMID: 37880871.

7. Bracamonte-Baran W, Čiháková D. Cardiac autoimmunity: myocarditis. Adv Exp Med Biol. 2017; 1003:187–221. PMID: 28667560.

8. Packer M. Do DPP-4 inhibitors cause heart failure events by promoting adrenergically mediated cardiotoxicity? Clues from laboratory models and clinical trials. Circ Res. 2018; 122:928–932. PMID: 29436388.

9. Moudgil R, Yeh ET. Mechanisms of cardiotoxicity of cancer chemotherapeutic agents: cardiomyopathy and beyond. Can J Cardiol. 2016; 32:863–870.e5. PMID: 27117975.